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Background & Aims: We evaluated the effects of ovari-
ectomy (OVX) and estrogen replacement treatment on
cholangiocyte proliferation induced by bile duct ligation
(BDL). Methods: BDL (2 weeks) was performed in ovari-
ectomized rats and the proliferative and apoptotic activ-
ity compared with normal, with BDL control rats, and
with BDL  OVX rats treated with 17- estradiol.
Results: OVX induced a signiﬁcant (P < 0.01) reduction
of bile duct mass in BDL rats. The reduction of bile duct
mass induced by OVX was associated with a decreased
expression of estrogen receptor (ER)- (2.5-fold) and,
mainly, ER- (35-fold). Proliferating cellular nuclear an-
tigen (PCNA) expression in cholangiocytes was impaired
by OVX, indicating depression of proliferation, whereas
terminal deoxynucleotidyl transferase-mediated de-
oxyuridine triphosphate nick-end labeling (TUNEL) and
Fas positivity were markedly enhanced, indicating acti-
vation of Fas-mediated apoptosis. Administration of
17- estradiol during BDL in OVX rats induced a normal-
ization of bile duct mass, ER expression, cholangiocyte
proliferation, and apoptosis (Fas and TUNEL) in compar-
ison with untreated BDL rats. Conclusions: Our ﬁndings
support the role of endogenous estrogens in sustaining
the enhanced proliferative and secretory activities of
cholangiocytes in cholestasis. On the basis of these
data, the hypothesis of an estrogenic functional deﬁ-
ciency in chronic cholestatic liver diseases should merit
careful attention.
Cholangiocytes, the epithelial cells lining the intra-hepatic biliary tree, are the target of damage in a
group of chronic cholestatic liver diseases (cholangiopa-
thies) recently classiﬁed as vanishing bile duct syndromes
(VBDS).1–6 These diseases are characterized by the pro-
gressive disappearance of intrahepatic bile ducts, which
leads to a severe ductopenic condition in terminal
stages.1–6 Cholangiocyte proliferation (another character-
istic feature of VBDS), inﬂuences, as a repair and com-
pensatory mechanism, the outcome of the disease and its
evolution toward the terminal ductopenic stage.1–6 For
this reason, a number of recent studies have focused on
agents and mechanisms involved in the modulation of
cholangiocyte proliferation.6–9
Estrogens are important inducers of cell growth and
differentiation10–12; however, until a few years ago, no
information was available on the role of estrogens and
their receptors on the modulation of cholangiocyte pro-
liferation. This is a very important topic, because most
VBDS, especially primary biliary cirrhosis, predominate
in women.1–6 In addition, indirect evidence suggests the
occurrence of estrogenic dysfunction in primary biliary
cirrhosis, including increased incidence of menstrual ir-
regularities, hysterectomy, breast cancer, and postmeno-
pausal osteoporosis.13–17 The latter (a sign of estrogen
deﬁciency) beneﬁts from estrogen replacement treat-
ment.18,19 Furthermore, marked alterations of estrogen
hepatic metabolism occur in cholestasis, which is one of
the hallmarks of cholangiopathies, caused by the de-
creased hepatic levels of P450-dependent microsomal
enzymes, with a consequently enhanced estradiol serum
level.20 We have recently shown the following8: (1) Rat
cholangiocytes express both estrogen receptor (ER)-
and ER- subtypes, which are overexpressed during
cholangiocyte proliferation induced by BDL; (2) estrogen
receptor antagonists impair BDL-induced cholangiocyte
proliferation; and (3) 17- estradiol stimulates in vitro
cholangiocyte proliferation. Together, these ﬁndings in-
dicate that estrogens and their receptors modulate
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cholangiocyte proliferation. To get more insights into
the role of estrogens in the modulation of cholangiocyte
proliferation, we evaluated the effect of ovariectomy
(OVX) and estrogen replacement treatment on cholan-
giocyte proliferation induced by BDL.
Materials and Methods
Normal female and ovariectomized Wistar rats (200–
250 g) were purchased from Charles River (Calco, Lecco, Italy).
Reagents were purchased from Sigma Chemical Co. (St. Louis,
MO) unless otherwise indicated. ICI 182,780 was purchased
from Tocris (Cookson Inc., Ballwin MO). Bile duct ligation or
bile duct incannulation (BDI, for bile collection) was per-
formed as described.7,21 OVX rats were submitted to BDL 3–5
weeks after OVX. Seventeen- estradiol was prepared as a
stock solution in dimethyl sulfoxide and administered subcu-
taneously, after dilution with saline (1:1000; total volume 0.5
mL), at the dose of 28 g/day starting 4 days before BDL and
continuing for 2 weeks thereafter. ICI 182,780 (1 mg/kg body
weight per day) was dissolved in benzylbenzoate/castor oil
mixture (20%/80% wt/wt) and administered subcutaneously
(100 L volume) starting 2 days before BDL and continuing
during 2-week BDL. The animals were killed, and liver his-
tology, immunohistochemistry, molecular, and functional
studies were performed. In preliminary experiments, sham-
OVX, sham-BDL, and the administration of the carrier for
17- estradiol or ICI 182,780 did not inﬂuence any of the
parameters measured. For this reason and to decrease the
number of experimental groups, these studies were included in
the same group (i.e., normal rats that include 3 normal rats, 3
sham-OVX rats, and 3 sham-BDL rats). Estradiol serum levels
were measured by a radioimmunoassay kit (Diagnostic Prod-
ucts Corporation, Los Angeles, CA). The study protocols were
in compliance with our institution’s guidelines.
Light Microscopy and
Immunohistochemical Studies on
Liver Samples
For light microscopy, small liver fragments (0.5 cm)
were ﬁxed in buffered formalin for 2–4 hours, embedded in
low-temperature fusion parafﬁn (55°C–57°C) and 3–4 m
sections stained with hematoxylin-eosin and Masson’s
trichrome stains. For immunohistochemical (IHC), sections
were mounted on glass slides coated with 0.1% poly-L-lysine.
After deparafﬁnation, endogenous peroxidase activity was
blocked by a 30-minute incubation in methanolic hydrogen
peroxide (2.5%). The endogen biotin was then blocked by
biotin Blocking System (code X0590; Dako, Copenhagen,
Denmark), according to the instructions supplied by the
vendor. Sections were hydrated in graded alcohol and rinsed
in phosphate-buffered saline (PBS; pH 7.4) before applying
the primary antibody. Sections were incubated overnight
at 4°C with monoclonal antibodies for the following: cytoker-
atin 19 (CK-19; Dako),22 PCNA (PC10; Dako), Fas (M-20)-
G (Santa Cruz Inc., Santa Cruz, CA), and with polyclonal
antibodies for ER- (PA1.1-310, Afﬁnity Bioreagents, Inc.,
Golden, CO). Samples were then rinsed with PBS for 5 min-
utes, incubated for 10 minutes at room temperature with
secondary biotinylated antibody (Dako LSAB2, code K0675;
Dako), with Dako ABC (code K0675; Dako), and, ﬁnally,
developed with 3-3 diaminobenzidine (DAB). For ER- de-
tection, we used a Dako Catalyzed Signal Ampliﬁcation (code
K1500; Dako) according to the instructions supplied by the
vendor. Samples were incubated overnight at 4°C with the
monoclonal primary antibodies: for ER- subtype, a cocktail
of 2 monoclonal antibodies C-314 and C-311 (50% of each8;
Santa Cruz Inc.). Sections were developed with DAB. For all
immunoreactions, negative and positive controls were also
included. Light microscopy and IHC microphotographs were
taken by Olympus BX-5 1 Light Microscopy with a Video-
cam (Spot Insight, Diagnostic Instrument, Inc., Sterling
Heights, MI) and processed with an Image Analysis System
(IAS-Delta Sistemi, Roma, Italy) software. Intrahepatic ductal
mass was evaluated7–9 in 6 blocks for each liver, randomly
taken from median lobe. Point count analysis was performed
by determining the number of ducts stained7–9 for either
-glutamyltranspeptidase (-GT) or CK-19, present in each
coded section (2–3-m thickness), obtained randomly. Light
microscopy images (10 or 20) were analyzed by using
Image Analysis System software (IAS-Delta Sistemi). For in
situ detection of apoptosis on the single cell, we used the
method of end labeling mediated by deoxynucleotidyl trans-
ferase (TdT) and labeling (terminal deoxynucleotidyl trans-
ferase-mediated deoxyuridine triphosphate nick-end labeling;
TUNEL) method (Apotag Kit; Oncor, Gaithersburg, MD).
Negative and positive controls were included in each bath of
slide. Morphological measurements were performed in a blind
fashion by 3 independent pathologists (E.G., P.O., A.F.) com-
ing from 2 different institutions, with an agreement always
higher than 90%.
Western Blot Analysis of Proliferating
Cellular Nuclear Antigen in Puriﬁed
Cholangiocytes
Pure preparations of cholangiocytes were obtained as
described7–9 from normal, BDL, BDL  OVX, and BDL 
OVX  17- estradiol-treated rats. Cholangiocyte prolifera-
tion was assessed by measurement of proliferating cellular
nuclear antigen (PCNA) protein expression by immunoblots as
described.7–9 The intensity of the bands was determined by
scanning video densitometry using the ChemiImager 4000
low-light imaging system (Alpha Innotech Corp., San Lean-
dro, CA). Purity of cholangiocyte preparation was assessed by
-glutamyltransferase (GGT) staining,7–9 and contamination
from hepatocytes was controlled by glucose-6-phosphatase23
staining. Virtually, all isolated cells were -GT positive, and
no glucose-6-phosphatase positive cell was found in cell prep-
arations from both normal and BDL livers, thus excluding
hepatocyte contamination.
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Statistical Analysis
All data are expressed as mean  SE. The differences
between groups were evaluated by analysis of variance
(ANOVA).
Results
Effect of OVX, BDL, and Estrogen
Replacement Treatment on Estradiol
Serum Levels
OVX induced a 3-fold decrease in the estradiol
serum levels of normal and BDL rats (P 	 0.01, Figure
1). However, 17- estradiol administration induced a
marked (P 	 0.01, Figure 1) increase in estradiol serum
levels of normal and BDL rats. When 17- estradiol was
administered during BDL in OVX rats, serum estradiol
levels rose higher (P 	 0.05, Figure 1) than BDL con-
trols. These ﬁndings indicate that the administered
amount of 17- estradiol was effective in restoring the
estrogen serum levels decreased by OVX.
Effects of OVX and Estrogen Replacement
Treatment on Bile Duct Mass, Cell
Proliferation, and Apoptosis
Neither OVX nor treatment with ICI 182,780 or
17- estradiol induces changes of intrahepatic bile duct
volume in normal rats (Figure 2). Parallel with previous
studies,1–9 2-week BDL induced a marked increase in
bile duct volume in comparison with normal rats (6.94%
 0.26% vs. 0.21%  0.09%, respectively, P 	 0.01;
Figure 2). However, when BDL was performed in rats
with OVX for 3–5 weeks, bile duct volume was de-
creased by approximately 30% (5.05%  0.34%, P 	
0.02) in comparison with control BDL rats (Figure 2),
indicating that induction of bile duct proliferation by
BDL was impaired by the ablation of ovaric function.
Administration of the selective antiestrogen ICI 182,780
during BDL induced a decrease in bile duct volume
(
50%; P 	 0.01), which was more pronounced (P 	
0.05) than that observed with OVX. When ICI 182,780
was administered during BDL in OVX rats, bile duct
volume was further decreased (
85%; P 	 0.01) in
comparison with BDL  OVX or BDL  ICI 182,780
(Figure 2). 17- estradiol treatment induced no effect on
bile duct volume of BDL rats. However, when 17-
estradiol was administered (starting 4 days before BDL)
during 2-weeks BDL in OVX rats, bile duct volume
(7.6%  0.55%) became similar to that of control BDL
rats (Figure 2). This indicates that the restoration of
estrogenic function through exogenous administration of
17- estradiol induces a normalization of the prolifera-
tive response of the intrahepatic biliary epithelium to
BDL.
Effect of OVX and Estrogen Replacement
Treatment on the IHC Expression of ER-
and ER-, Cholangiocyte Proliferation,
and Apoptosis
OVX, ICI 182,780, and 17- estradiol did not
inﬂuence the IHC expression of ER-, ER-, PCNA,
Fas, or TUNEL positivity in normal rats (Figures 3–8).
As far as immunohistochemistry for ER is concerned, the
stain for ER- was nuclear, whereas that for ER- was
cytoplasmic given the characteristic of the antibody used
that resulted in similar cytoplasmic staining in positive
control tissues, including the uterus. BDL induced a
marked (P 	 0.01) increase in the percentage of cholan-
giocytes positive for ER- or ER- in comparison with
normal rats (Figures 3 and 4). However, the increase of
ER- positivity (35-fold) was much more pronounced
than that of ER- (3.5-fold). When BDL was performed
in OVX rats, the percentage of cholangiocytes positive
for ER- or ER- decreased (P 	 0.01) in comparison
with BDL rats (
32% and 
45%, respectively; Figures
3 and 4). The administration of the antiestrogen ICI
182,780 during BDL decreased ER- positivity (per-
centage cholangiocytes) by a similar extent (
31%; P 	
0.01) than OVX, but it induced a dramatic effect on
ER- expression, which was decreased by 94% (P 	
0.01) and became similar to normal rats (Figures 3 and
4). When ICI 182,780 was administered during BDL in
OVX rats, the IHC expression of ER- or ER- was
Figure 1. Measurement of estradiol serum levels. OVX decreased
more than 3-fold estradiol serum levels in normal and BDL rats (N vs.
N  OVX and BDL vs. BDL  OVX). 17- E administration induced a
marked increase of estradiol serum levels (N vs. N  17- E, BDL vs.
BDL  17- E, BDL  OVX vs. BDL  OVX  17- E). *P 	 0.05 vs.
the other groups. Data are mean  SE of n  5–9. Abbreviations: N,
normals; OVX, ovariectomy; BDL, bile duct ligation; ICI, ICI 182,780;
17- E, 17- estradiol.
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further decreased (
52% and 
97%, respectively) in
comparison with BDL  OVX or BDL  ICI 182,780-
treated rats (Figures 3 and 4). 17- estradiol adminis-
tration showed no effect in BDL rats but completely
restored (similar to BDL) the IHC expression of ER-
and ER- when administered during BDL in OVX rats
(Figures 3 and 4).
The decreased proliferative response of intrahepatic
bile ducts to BDL in OVX rats was caused by both
impaired cholangiocyte proliferation and enhanced Fas-
mediated apoptotic cholangiocyte death. The impaired
cholangiocyte proliferation in OVX rats was showed by
immunohistochemistry for PCNA (Figure 5). The per-
centage of PCNA-positive cholangiocytes, in fact, was
signiﬁcantly lower in BDL  OVX than in BDL rats
Figure 2. Bile duct volume evaluated by quantitative morphometry
after immunostaining with CK-19. (A) Bar graph. OVX treatment with
ICI 182,780 and 17- estradiol induced no signiﬁcant changes in bile
duct volume in normal rats. Two-week BDL induced a very large
increase of bile duct volume in comparison with normal rats (*P 	
0.01). When BDL was performed in OVX rats, bile duct volume was
decreased in comparison with control BDL rats (&P 	 0.02). ICI
182,780 administered during BDL induced a decrease in bile duct
volume, which was more pronounced than that observed with OVX
(i.e., ICI  BDL vs. BDL  OVX; £P 	 0.05). When ICI 182,780 was
administered during BDL in OVX rats (BDL  OVX  ICI), bile duct
volume was further decreased in comparison with BDL  OVX or
BDL  ICI 182,780 (§P 	 0.01). 17- estradiol treatment had no
effect on bile duct volume of BDL rats (BDL  17- E vs. BDL), but,
when administered during 2 weeks of BDL in OVX rats, it induced a
normalization (i.e., similar to control BDL) of bile duct volume (BDL 
OVX  17- E vs. BDL  OVX). Data are mean  SE of n  5–9. For
abbreviations see Figure 1 legend. (B) Pictures of (1) normal, (2) BDL,
(3) BDL  OVX  ICI, and (4) BDL  OVX  17- estradiol are shown
(original magniﬁcation 20).
Figure 3. Immunohistochemistry for estrogen receptor ER- in the
liver. (A) Bar graph. The percentage of cholangiocyte positive for ER-
was similar between normal, normal  OVX rats, normal  ICI
182,780, and normal  17- estradiol. BDL induced a marked in-
crease in the percentage of cholangiocytes positive for ER- in com-
parison with normal rats (BDL vs. N; *P 	 0.01). When BDL was
performed in OVX rats, the percentage of cholangiocytes positive for
ER- decreased in comparison with BDL rats (BDL  OVX vs. BDL;
&P 	 0.01). The administration of the antiestrogen ICI 182,780
during BDL decreases ER- positivity (percentages cholangiocytes) to
a similar extent than OVX (BDL ICI vs. BDL OVX and vs. BDL; £P	
0.01). When ICI 182,780 was administered during BDL in OVX rats,
the IHC expression of ER- was further decreased (BDL  ICI  OVX
vs. BDL  ICI and vs. BDL  OVX; §P 	0.01). 17- estradiol admin-
istration showed no effect in BDL rats but completely restored (i.e.,
similar to BDL) the IHC expression of ER- when administered during
BDL in OVX rats (BDL  OVX  17- E vs. BDL  OVX and vs. BDL).
Data are mean  SE of n  5–9. For abbreviations see Figure 1
legend. (B) Pictures of (1) normal, (2) BDL, (3) BDL  OVX  ICI, and
(4) BDL  OVX  17- estradiol are shown (original magniﬁcation
40).
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(P 	 0.05; Figure 5). The antiestrogen ICI 182,780
induced a decrease (P 	 0.05) of PCNA positivity in
cholangiocytes, which was similar to the effect observed
in OVX rats and displayed an additive effect with
OVX when administered during BDL (Figure 5). 17-
estradiol treatment showed no effect on BDL rats but
completely normalized PCNA positivity in BDL 
OVX rats where PCNA positivity became similar to
untreated BDL rats (Figure 5). In selected experiments,
PCNA protein expression was also measured by immu-
noblots in pure cholangiocytes from normal (n  3),
BDL (n  3), BDL  OVX (n  3), or BDL  OVX
17- estradiol ( n  3) treated rats (Figure 6). Con-
sistent with IHC data, BDL induced a marked (P 	
0.01) increase in PCNA protein expression in cholangio-
cytes, which was decreased (P 	 0.01; Figure 6) when
BDL was performed in OVX rats. The effect of OVX on
PCNA protein expression in BDL rats was completely
reverted by 17- estradiol administration (P 	 0.01;
BDL  OVX  17- estradiol vs. BDL  OVX;
Figure 6).
Positivity for Fas and TUNEL involved less than 2.5%
cholangiocytes of BDL rats (Figures 7 and 8). When BDL
Figure 4. Immunohistochemistry for estrogen receptor ER- in liver
sections. (A) Bar graph. The percentage of cholangiocyte positive for
ER- was similar between normal, normal  OVX rats, normal  ICI
182,780, and normal  17- estradiol. BDL induced a marked in-
crease in the percentage of cholangiocytes positive for ER- in com-
parison with normal rats (BDL vs. N; *P 	 0.01). When BDL was
performed in OVX rats, the percentage of cholangiocytes positive for
ER- decreased in comparison with BDL rats (BDL  OVX vs. BDL;
&P 	 0.01). The administration of the antiestrogen ICI 182,780
during BDL induced a dramatic decrease of ER- positivity in cholan-
giocytes (£P 	 0.01 vs. BDL or BDL  OVX). 17- estradiol adminis-
tration showed no effect in BDL rats but completely restored the
immunohistochemical expression of ER- (i.e., similar to BDL) when
administered during BDL in OVX rats (BDL  OVX  17- E vs. BDL 
OVX). Data are mean  SE of n  5–9. For abbreviations see Figure
1 legend. (B) Pictures of (1) normal, (2) BDL, (3) BDL OVX ICI, and
(4) BDL  OVX  17- estradiol are shown (original magniﬁcation
40).
Figure 5. Immunohistochemistry for PCNA in liver sections. (A ) Bar
graph. The percentage of cholangiocyte positive for PCNA was similar
between normal, normal  OVX rats, normal  ICI 182,780, and
normal  17- estradiol. BDL induced a marked increase of the
percentage PCNA positive cholangiocytes (BDL vs. N; *P 	 0.01),
which was decreased when BDL was performed in OVX rats (BDL 
OVX vs. BDL; &P 	 0.05). The antiestrogen ICI 182,780 decreases
PCNA positivity in cholangiocytes of BDL rat livers (BDL  ICI vs. BDL;
£P 	 0.05) to a similar extent than the effect observed by OVX and
displayed an additive effect with OVX (BDL  OVX  ICI vs. BDL  ICI
or BDL OVX; §P	 0.05). 17- estradiol treatment showed no effect
on BDL rats but completely normalized (i.e., similar to BDL controls)
PCNA positivity in BDL  OVX (BDL  OVX 17- E vs. BDL and vs.
BDL  OVX). Data are mean  SE of n  5–9. For abbreviations see
Figure 1 legend. (B) Pictures of (1) normal, (2) BDL, (3) BDL  OVX 
ICI, and (4) BDL  OVX  17- estradiol are shown (original magni-
ﬁcation 40).
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was performed in OVX rats, there was a signiﬁcant (P 	
0.01) increase in the number of cholangiocytes express-
ing Fas (6%), which were also positive by TUNEL
analysis (Figures 7 and 8). Treatment of BDL rats with
the antiestrogen ICI 182,780 resulted in a dramatic
increase (P 	 0.01) of Fas and TUNEL positivity (more
than 60% cholangiocytes, which was only slightly fur-
ther increased when the antiestrogen was administered in
OVX rats during BDL; Figures 7 and 8). The adminis-
tration of 17- estradiol in BDL rats induced no effect on
Fas and TUNEL positivity, but, when the estrogen re-
placement treatment was performed in OVX rats during
BDL, a complete normalization of Fas and TUNEL was
observed, which was similar to BDL rats in the absence
of any treatment (Figures 7 and 8). These ﬁndings sug-
gest that OVX induced a slight activation of Fas-medi-
ated apoptosis in BDL rats, which was completely re-
verted by estrogen replacement treatment. A dramatic
activation of Fas-mediated apoptosis was observed when
ER receptors were blocked by ICI 182,780.
Discussion
The study shows that (1) OVX impairs the pro-
liferative response of intrahepatic bile ducts to experi-
mental cholestasis (BDL) as showed by the signiﬁcant
lower intrahepatic bile duct volume of BDL OVX rats
than BDL controls; (2) the decreased intrahepatic bile
duct mass of OVX rats after BDL was associated with
decreased cholangiocyte proliferation (as shown by the
lower PCNA expression) and with enhanced Fas-medi-
ated apoptosis of proliferating cholangiocytes as shown
by immunohistochemistry for Fas and by TUNEL anal-
ysis; (3) exogenous administration of 17- estradiol in
OVX rats normalizes the proliferative response of the
intrahepatic bile ducts to BDL (bile duct volume) by
restoring proliferation (PCNA) and ablating Fas-medi-
ated apoptosis (Fas and TUNEL) in cholangiocytes; and
(4) the negative effects of OVX on the proliferative
capacity of cholangiocytes during BDL were associated
with a decreased IHC expression of ER- and ER- in
proliferating cholangiocytes; this effect also was reversed
by estrogen replacement treatment. Taken together,
these ﬁndings are consistent with a role of endogenous
estrogens in modulating cholangiocyte proliferation dur-
ing experimental cholestasis.
Cholangiocyte proliferation is a typical response of the
liver to bile duct obstruction, which was reproduced
experimentally in the BDL rat model.1–6 In this exper-
imental model of selective cholangiocyte proliferation, a
number of factors have been considered to play a role in
the induction and maintenance of proliferative response,6
including the increased endoluminal pressure and the
local or systemic release of growth factors (HGF, IGF1,
EGF) and cytokines (interleukin-6).6 Based on indirect
and direct evidence, we have recently proposed that
estrogens and their receptors play an important role in
modulating cholangiocyte proliferation.8 The indirect
evidence was based on the inhibitory effect of estrogen
antagonists (tamoxifen and ICI 182,780) on cholangio-
cyte proliferation induced by BDL, whereas the direct
evidence was based on the in vitro ability of 17- estra-
diol to stimulate cholangiocyte proliferation.8 In the
present study, we approached the same topic by evalu-
ating the effects of ablation of ovaric function (by OVX)
on the proliferative response of intrahepatic bile ducts to
BDL. Three to 5 weeks after OVX, rats underwent BDL
and, subsequently, the proliferative response of cholan-
giocytes was compared with BDL control rats. Estradiol
serum levels were measured in the different experimental
groups with the evidence that the absence of ovaric
function (by OVX) resulted in a 3-fold decrease of estra-
diol serum levels, with the residual serum estrogens
originating mainly from the adrenal gland. Parallel with
other studies,8,20 BDL resulted in a marked increase of
estradiol serum levels because of the impaired metabo-
lism and biliary excretion of endogenous estrogens. Es-
trogen serum levels were virtually doubled after OVX
rats underwent BDL for 2 weeks, but still persisted
2.5-fold lower than control BDL. Finally, the doses of
17- estradiol administered in OVX  BDL rats were
Figure 6. Western blot analysis of PCNA in isolated cholangiocytes.
Cholangiocytes isolated from BDL rats showed a PCNA protein expres-
sion markedly higher than normal rats. When BDL was performed in
OVX rats, PCNA in cholangiocytes markedly decreased, but this effect
of OVX was completely restored by 17- estradiol replacement treat-
ment. Mean  SE of n  3 are shown in the bar graph. *P 	 0.01 vs.
normal; &P 	 0.01 vs. BDL; P 	 0.01 vs. BDLOVX.
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effective in increasing serum estradiol at levels similar to
BDL control rats. Having shown that OVX was effective
in depressing endogenous estrogen levels and that the
estrogen replacement treatment was able to reverse the
effects of OVX, we demonstrated that OVX induces an
impaired proliferative response of the intrahepatic bile
duct system to BDL. The intrahepatic bile duct volume
of BDL  OVX rats was in fact 30% less than control
BDL rats with an intact ovaric function as evaluated by
quantitative morphometry. The effect of OVX was lower
than that obtained by blocking endogenous estrogens
with the pure ER antagonist ICI 182,780, and an almost
complete block of BDL-induced expansion of bile duct
volume was obtained only when the 2 treatments were
combined (i.e., OVX  ICI 182,780). The impaired
response of intrahepatic bile duct volume to bile duct
obstruction in OVX rats was caused mainly by an im-
paired cell proliferation as evidenced by PCNA immu-
nostaining and immunoblotting but also by a slight
activation of Fas-mediated apoptotic cell death. This was
Figure 7. Immunohistochemistry for Fas in the liver. (A) Bar graph.
The percentage of cholangiocytes positive for Fas was less than 2.5%
cholangiocytes in normals, normals OVX, normals ICI, normals
17- E, and BDL rats. When BDL was performed in OVX rats, the
percentage of cholangiocyte Fas positivity signiﬁcantly increased
(BDL  OVX vs. BDL). Treatment of BDL rats with the antiestrogen ICI
182,780 resulted in a dramatic increase of Fas positivity in cholan-
giocytes (BDL  ICI vs. BDL). The administration of 17- estradiol in
BDL rats induced no effect on Fas positivity (BDL  17- E vs. BDL),
but, when the estrogen replacement treatment was performed in OVX
rats during BDL, a complete normalization of Fas positivity was ob-
served (BDL  OVX  17- E vs. BDL  OVX and vs. BDL), which
become similar to BDL rats in the absence of any treatment. Data are
mean SE of n 5–9. *P	 0.05 vs. all the other groups; &P	 0.05
vs. all the other groups but not BDL  OVX  ICI; £P 	 0.05 vs. the
other groups but not BDL  ICI. For abbreviations Figure 1 legend. (B)
Pictures of (1) normal, (2) BDL, (3) BDL  OVX  ICI, and (4) BDL 
OVX  17- estradiol are shown (original magniﬁcation 40).
Figure 8. TUNEL analysis liver sections. (A) Bar graph. The percent-
age of cholangiocytes positive at the TUNEL analysis was less than
2.5% cholangiocytes in normals, normals  OVX, normals  ICI,
normals  17- E, and BDL rats. When BDL was performed in OVX
rats, the percentage of cholangiocyte TUNEL positivity signiﬁcantly
increased (BDL  OVX vs. BDL). Treatment of BDL rats with the
antiestrogen ICI 182,780 resulted in a dramatic increase of TUNEL
positivity in cholangiocytes (BDL  ICI vs. BDL), which was only
slightly increased when the antiestrogen was administered during
BDL in OVX rats (BDL OVX ICI vs. BDL OVX). The administration
of 17- estradiol in BDL rats induced no effect on TUNEL positivity
(BDL  17- E vs. BDL), but, when the estrogen replacement treat-
ment was performed in OVX rats during BDL, a complete normalization
of TUNEL positivity was observed (BDL  OVX  17- E vs. BDLOVX
and vs. BDL), which become similar to BDL rats in the absence of any
treatment. Data are mean  SE of n  5–9. *P 	 0.05 vs. all the
other groups; &P	 0.05 vs. all the other groups but not BDL OVX
ICI; £P 	 0.05 vs. all the other groups but not BDL  ICI. For
abbreviations see Figure 1 legend. (B) Pictures of (1) normal, (2) BDL,
(3) BDL  OVX  ICI, and (4) BDL  OVX  17- estradiol are shown
(original magniﬁcation 40).
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different from what was observed when endogenous es-
trogens were blocked by the pure ER antagonist ICI
182,780, where a dramatic activation of Fas-mediated
apoptosis was observed. The fact that antiestrogens and
speciﬁcally ICI 182,780 may induce apoptosis of target
cells expressing ER has been previously shown, and this
correlates with their growth inhibitory action.24,25 The
proapoptotic effect of antiestrogens occurs through mul-
tiple mechanisms other than the block of the estrogen
mitogenic effect, including down-regulation of the anti-
apoptotic protein bcl-2 or inhibition of calmodulin-
dependent survival signals.24–26 The latter could be of
relevance in proliferating cholangiocytes, where intracel-
lular Ca2, protein kinase C, and calmodulin-dependent
signals play a role in sustaining cholangiocyte prolifera-
tive machinery.7,9 Thus, in evaluating the role of endog-
enous estrogens as modulators of the cholangiocyte pro-
liferative response to experimental cholestasis, the effects
of OVX seem to be different from those of antiestrogens,
because the latter are characterized by a marked proapop-
totic effect.
The effect of OVX on cholangiocyte proliferation was
associated with a 40%–50% lower IHC expression of
both ER- and ER-, indicating that the down-regula-
tion of both receptor subtypes as a consequence of OVX-
induced estrogen depletion is the mechanism involved.
In contrast, the antiproliferative effect of ICI 182,780 is
associated with an almost complete ablation of ER-,
and this is consistent with recent data suggesting a
central role played by ER- in mediating growth-inhib-
itory action of antiestrogens.27 The pronounced effect of
the antiestrogen ICI 182,780 on both ER- expression
and apoptosis could suggest a role of this receptor (once
activated by the selective agonists) in the down-regula-
tion of apoptotic machinery. However, in some cell
types, ER- plays an antiproliferative action,28 antago-
nizing the positive modulatory effects of ER-. In
cholangiocytes, the present and previous studies8 suggest
that both ER- and ER- play a role in mediating the
positive modulatory effects of endogenous estrogens on
cholangiocyte proliferation. Finally, we showed that ex-
ogenous administration of 17- estradiol completely re-
versed the effects of OVX on bile duct mass, ER expres-
sion, cell proliferation, and apoptosis. These ﬁndings
support the speciﬁcity of OVX effects, which are due to
depressed estrogen levels and not to other confounding
factors. Regarding this, it is well known that estrogens
may induce cholestasis by affecting the function and
protein expression of different transporters in hepato-
cytes,29 thus, it may be argued that the effect of 17-
estradiol could be a consequence of its cholestatic effect.
We may exclude the latter possibility, because, in our
study, estrogen replacement treatment was performed
using a dose 30–50-fold lower than that used to induce
experimental cholestasis. In addition, estradiol (even at a
cholestatic dose for hepatocytes) does not affect the se-
cretory activities of rat intrahepatic biliary epithelium.30
In conclusion, our ﬁndings give further support to the
role of endogenous estrogens as modulators of cholangio-
cyte proliferation in the course of cholestasis. In our
opinion, estrogens act by synergizing the effects of
growth factors in sustaining the proliferative machinery
and depressing apoptosis. The fact that neither OVX nor
exogenous estrogens has any effect on cholangiocyte pro-
liferation in normal rats is consistent with this hypoth-
esis because cholangiocytes are quiescent cells in the
normal status6 and become proliferating only under cer-
tain experimental or clinical conditions where a complex
network of growth factors is activated.7,9 In addition,
when the estrogenic function was almost completely
blocked by combining OVX and antiestrogens, cholan-
giocyte proliferation (evaluated by PCNA) still persists,
and this indicates that, even in the absence of the estro-
gen synergizing effect, the growth factors still continue
to exhibit their action, although at a lower level.
Cholangiocyte proliferation plays an important role as
a repair and compensatory mechanism for bile duct loss
during cholangiopathies, therefore, counteracting the
evolution of the disease toward the terminal ductopenic
stage. Estrogens and their metabolites have often been
considered to have a pathogenic role in these diseases,
which preferentially affects women.13,30 This is especially
true for primary biliary cirrhosis, where an estrogenic
functional deﬁciency has been hypothesized.13,31 Results
from our study further highlight this hypothesis, as a
mechanism favoring the clinical appearance or a more
rapid progression of the disease, and encourage clinical
studies aimed to ﬁnd deﬁnitive demonstrations.
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